Barclays analyst Gena Wang raised the firm’s price target on Cytokinetics (CYTK) to $71 from $53 and keeps an Overweight rating on the shares. The firm says it has more conviction for aficamten’s opportunity and further differentiation from mavacamten following this weekend’s data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics Reveals Promising MAPLE-HCM Trial Results
- Kraft Heinz announces separation, Elliott builds $4B PepsiCo stake: Morning Buzz
- Cytokinetics rises 34.5%
- Promising Phase 3 Trial Results Bolster Buy Rating for Cytokinetics’ Aficamten
- H.C. Wainwright sees ‘little room left for doubt’ on Cytokinetics’ aficamten